OncoGenex Pharmaceuticals shares fell 60.3% after the company and its partner Teva Pharmaceutical Industries revealed that custirsen did not significantly improve survival versus chemotherapy for prostate cancer patients enrolled in the Phase III SYNERGY clinical trial.
Bothell, Washington-based OncoGenex closed at $3.85 per share on 28 April versus $9.70 before the weekend. The company shed $86.1m...